Longeveron News and Activities

Longeveron is a company listed under the stock ticker LGVN (US).

View the org chart displaying its 19 main executives

Most searched biographies at Longeveron

• Stephen Willard, Chief Executive Officer
• Rock Soffer, Director
• Ursula Ungaro, Director

Popular executive movements at Longeveron

• Stephen Willard has joined the company as Chief Executive Officer  (posted on February 18 2026).
• George Paletta has joined the company as Director  (posted on October 2 2025).

Create your alert
to follow the executive moves at Longeveron.

Longeveron has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Longeveron

• Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
• Longeveron to Present at BIO International Convention 2026
• Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
• Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
• Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
• Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
• Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
• Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
• Longeveron Announces Closing of Private Placement of up to $30 Million
• View more press releases Close

Social media about Longeveron

• Longeveron on Wikipedia, Google News & Yahoo Finance
• Longeveron on LinkedIn, X (Twitter) & YouTube